Combination of the ABL kinase inhibitor imatinib with the Janus kinase 2 inhibitor TG101348 for targeting residual BCR-ABL-positive cells

Seiichi Okabe*, Tetsuzo Tauchi, Seiichiro Katagiri, Yuko Tanaka and Kazuma Ohyashiki

Abstract
Background: The ABL kinase inhibitor imatinib is highly effective in treating most, but not all, patients with chronic myeloid leukemia (CML). This is because residual CML cells are generally present in the bone marrow microenvironment and are refractory to imatinib. Hematopoietic cytokine receptor signaling is mediated by Janus kinases (JAKs) and their downstream transcription factor, signal transducer and activator of transcription (STAT). TG101348 (SAR302503) is an oral inhibitor of JAK2.

Methods: We investigated the efficacy of imatinib and TG101348 using the break point cluster region-c-Abelson (BCR-ABL)-positive cell line and primary CML samples wherein leukemia cells were protected by a feeder cell line (HS-5).

Results: Imatinib treatment resulted in partial inhibition of cell growth in HS-5-conditioned medium. Furthermore, combined treatment with imatinib and TG101348 abrogated the protective effects of HS-5-conditioned medium on K562 cells. Phosphorylation of Crk-L, a BCR-ABL substrate, decreased considerably, while apoptosis increased. In addition, the combined treatment of CD34-positive primary samples resulted in considerably increased cytotoxicity, decreased Crk-L phosphorylation, and increased apoptosis. We also investigated TG101348 activity against feeder cells and observed that STAT5 phosphorylation, granulocyte macrophage colony-stimulating factor, and interleukin 6 levels decreased, indicating reduced cytokine production in HS-5 cells treated with TG101348.

Conclusions: These results showed that JAK inhibitors may enhance the cytotoxic effect of imatinib against residual CML cells and that a combined approach may be a powerful strategy against the stroma-associated drug resistance of Philadelphia chromosome-positive cells.

Keywords: Chronic myeloid leukemia, JAK2 inhibitor, Imatinib, Cytokine, Feeder cell

Background
Chronic myeloid leukemia (CML) is a malignant myeloproliferative clonal disorder associated with the presence of the Philadelphia chromosome (Ph) [1]. Ph results from a translocation that yields the break point cluster region-c-Abelson (BCR-ABL) fusion protein, which is a constitutively active tyrosine kinase [2]. BCR-ABL activation is responsible for modulating different signaling pathways, and consequently, hematopoietic stem and progenitor cell proliferation, as well as abnormal interactions with the extracellular matrix and stroma [3]. The BCR-ABL fusion protein activates several downstream signaling molecules, including those of the Ras/Raf/MAPK, PI3K/AKT/mTOR, and JAK/STAT pathways [4-6].

Imatinib, a first generation ABL tyrosine kinase inhibitor (ABL TKI), is a competitive inhibitor that binds to the ATP-binding catalytic site of ABL and decreases kinase domain activity by stabilizing the protein in an active conformation [7]. Imatinib is highly for treating patients in the chronic phase of CML. As observed in the International Randomized Study of Interferon and STI571 study, 87% of patients treated with imatinib achieved a complete cytogenetic response, with many patients achieving major molecular responses [8]. However, discontinuing imatinib is usually associated with disease relapse. In particular, the French Stop Imatinib trial reported that approximately 60% of patients who had maintained a complete molecular
response for 2 years on imatinib relapsed after termination of treatment [9]. Thus, it is currently recommended that patients with CML stop TKI therapy only in the context of a clinical trial. The major cause of relapse in patients with CML is considered to be the existence of leukemia stem cells as imatinib is believed to be unable to kill quiescent CML stem cells. It is possible that these quiescent leukemia stem cells do not depend on BCR-ABL signaling [10]. Therefore, new strategies are required to specifically target CML stem cells and improve outcomes in patients with CML.

Janus kinases (JAKs) are a family of intracellular, non-receptor tyrosine kinases including four family members such as JAK1, JAK2, JAK3, and Tyk2. JAK signaling pathways are required for cytokine and growth factor signaling [11]. The downstream molecules, which belong to the signal transducer and activator of transcription (STAT) family, are activated by JAKs. The JAK/STAT pathway is responsible for various functions. JAK2 plays an important role in the signaling pathways induced by hematopoietic growth factors such as granulocyte macrophage colony-stimulating factor (GM-CSF) and interleukin (IL)-3 [12,13]. Although JAK2 is phosphorylated in cytokine-independent BCR-ABL-positive CML cells, aberrant JAK/STAT signaling has been implicated in various tumors [14]. For example, a point mutation in JAK2 that results in non-synonymous amino acid substitution, V617F, was discovered in hematological malignancies. In fact, the V617F variant is common in patients with myeloproliferative neoplasms (MPNs) such as polycythemia vera, essential thrombocytopenia, and primary myelofibrosis [15]. Several JAK2 inhibitors have been developed for patients with MPNs. These inhibitors are currently in clinical trials. One of the JAK2 inhibitors, TG101348 (also known as SAR302503), is a small-molecule JAK2 antagonist. TG101348 inhibits the growth of hematopoietic cells derived from patients with MPNs who have the V617F mutation [16].

JAK2 is part of the BCR-ABL signaling network pathway and is activated in CML cells [17]. JAK2 including the point mutation is also involved in CML maintenance [18-20]. Thus, JAK2 inhibitors may become a therapeutic target for CML cells. Although several reports have demonstrated that BCR-ABL/JAK2 inhibits CML cells including ABL TKI-resistant cells [21,22], it is not completely known whether JAK2 is involved in CML stem cell survival mediated by cytokines in the presence of ABL TKI.

Here, we investigated the effect of TG101348 on residual CML cells. We demonstrated that co-treatment with imatinib and TG101348 increased the cytotoxic effect in CD34-positive CML samples. We also found that cytokine production, which supported growth of CML cells, was reduced by TG101348.

Results

Effects of imatinib on BCR-ABL-expressing cells in the presence of human stromal cells

We investigated the cell proliferation effects of imatinib on K562 cells when cultured in the presence or absence of HS-5 conditioned medium, which was collected and pooled from a HS-5 stromal cell culture. We found that K562 cell proliferation was inhibited by imatinib in a dose-dependent manner when cultured in the absence of HS-5 conditioned medium (Figure 1A). In contrast, we observed that anti-leukemic activity of imatinib was partially reduced in the presence of HS-5 conditioned medium (Figure 1A). The HS-5 stromal cell line secretes several cytokines [23]. As JAK2 is essential for signaling of several of these cytokines, we used the JAK2 inhibitor TG101348 to investigate the role of JAK2 in the observed protection of K562 cells by HS-5 conditioned medium. We found that co-treatment with imatinib and TG101348 inhibited K562 cell proliferation in the presence of the HS-5 conditioned medium (Figure 1B). We also found that another JAK inhibitor, AG490, also inhibited K562 cell growth in the presence of HS-5 conditioned medium (Figure 1B). We next investigated the effect of TG101348 alone on K562 cells. We found that high TG101348 concentration partially inhibited K562 cell proliferation in the absence of the HS-5 conditioned medium (Figure 1C). The IC50 value for TG101348 was up to 2 μM in BCR-ABL-positive cells. The concentration of TG101348 used in a clinical trial was >1 μM [16]. It has been reported that a high TG101348 concentration is associated with severe adverse events in patients with MF [16], thus, we investigated concentrations below <1 μM in this study. Next, we investigated the effects of this inhibitor on intracellular signaling. We observed a decrease in BCR-ABL and STAT5 phosphorylation in the presence of a high TG101348 concentration (Figure 1D).

Treatment of Ph-positive (Ph+) leukemia cells with imatinib and TG101348

We next investigated whether imatinib and TG101348 could inhibit Ph+ cell growth in the presence of HS-5 cells. K562 cells were exposed to imatinib alone or in combination with TG101348 at different concentrations in the presence or absence of HS-5 cells. Growth of K562 cells treated with imatinib alone in the absence of HS-5 was considerably inhibited in a dose-dependent manner. However, when K562 cells were treated in the presence of HS-5 cells, the effects of imatinib decreased considerably (Figure 2A). Thus, HS-5 cells supported K562 cell proliferation even in the presence of a high imatinib concentration. Next, we investigated the effect of TG101348 treatment. We observed that cell contact between K652 and HS-5 cells was required for protection from imatinib. We also found that treatment with
TG101348 overcame the HS-5-mediated protection of K562 cells (Figure 2A). Using immunoblotting, we determined that phosphorylation of Crk-L, a BCR-ABL substrate, STAT5, and mitogen activated protein kinase (MAPK) decreased following co-treatment with imatinib and TG101348. In contrast, we observed that poly(ADP-ribose) polymerase (PARP) activity increased during co-treatment (Figure 2B). Next, we used the pan-caspase inhibitor Z-VAD-fmk to inhibit caspase pathways. We found that Z-VAD-fmk treatment inhibited imatinib- and TG101348-induced apoptosis, suggesting that a caspase-dependent mechanism is involved in TG101348- and imatinib-mediated cell death in K562 cells (Figure 2C).

Effects of TG101348 in combination with imatinib on CD34-positive CML samples
To determine whether co-treatment with TG101348 and imatinib affects primary chronic phase CML cell viability, we isolated untreated peripheral blood samples from patients at the time of diagnosis or healthy donors and cultured the cells in the presence of HS-5 cells for 72 h with either imatinib alone or in combination with TG101348 at the indicated concentrations (Figure 3A). Cell viability was assessed by trypan blue exclusion. Viability of CD34-positive primary cells was not affected by imatinib treatment alone or in the presence of HS-5 stromal cells (Figure 3A). In contrast, viability of the
Figure 2 (See legend on next page.)
primary cells decreased significantly by imatinib in the absence of HS-5 cells (data not shown). However, co-treatment with TG101348 and imatinib resulted in a progressive reduction in viable cell number compared with treatment with imatinib alone (Figure 3A). Furthermore, viable cell numbers of normal samples decreased partially after treatment with imatinib and TG101348 suggests that these treatments were selectively, and more effectively influence against leukemia (Figure 3A). The efficacy of the co-treatment was different in each group of primary samples, which may indicate different chemical sensitivities of these compounds. We next investigated the effect of the inhibitors on intracellular signaling in CD34-positive primary samples. We found that BCR-ABL, Crk-L, and STAT5 phosphorylation decreased, while PARP activity increased after the co-treatment (Figure 3B). We investigated the efficacy of co-treatment with TG101348 and imatinib in a xenograft model. Growth of tumors decreased considerably in TG101348- and imatinib-treated mice compared with that in control mice. These results indicate that co-treatment with imatinib and TG101348 is an effective strategy to reduce expansion of BCR-ABL-positive cells including CD34-positive primary cells.

**Knockdown of JAK2 increased sensitivity to imatinib**

We next knocked down JAK2 by transfecting JAK2 small interfering RNA (siRNA) into K562 cells. Cell lysates were analyzed by immunoblotting 72 h after transfection using an anti-JAK2 Ab. We confirmed that Jak2 expression decreased considerably when compared to that in control cells (Figure 4A). To test the effect of JAK2 knockdown on K562 cells, we examined the effect of imatinib on them when cultured in the presence of HS-5. We observed that the viability of JAK2 siRNA transfected cells was not reduced when compared with that of control cells (Figure 4B). In contrast, viability of JAK2 siRNA-transfected cells was partially reduced in the presence of HS-5 cells when compared to control cells cultured under the same conditions (Figure 4B). Importantly, we found that viability of JAK2 siRNA-transfected K562 cells decreased considerably after imatinib treatment in the presence of HS-5 cells (Figure 4B). Next, we investigated the effect of imatinib on intracellular signaling in these cells. We found that BCR-ABL phosphorylation in the JAK2 siRNA-transfected K562 cells was not reduced after imatinib treatment compared to control cells (Figure 4C). In contrast, we observed that Crk-L and MAPK phosphorylation decreased after imatinib treatment in JAK2-siRNA transfected K562 cells (Figure 4C). Thus, these results indicate that JAK2 is involved in the downstream signaling of BCR-ABL.

**Detection of cytokines in HS-5 conditioned medium**

The HS-5 cell line was treated with TG101348 at different concentrations for 24 h (Figure 5). We found that STAT5 phosphorylation was partially reduced after TG101348 treatment using immunoblotting analysis (Figure 5A). We next investigated cytokine levels by assaying HS-5 conditioned medium after 1 day of culture in the presence or absence of TG101348 using the human cytokine array according to the manufacturer’s instructions. We analyzed 36 cytokines simultaneously and evaluated their relative expression levels. We found that GM-CSF, and IL-6 levels decreased considerably after TG101348 treatment compared to that in the untreated conditioned medium (Figure 5B). These results indicate that TG101348 regulates cytokine production in HS-5 cells.

**Discussion**

Previous studies revealed that BCR-ABL-positive progenitor cells persist in patients with CML despite TKI therapy. This may be attributable, in part, to quiescent CML stem cells residing in protected hematopoietic niches [24]. Hematopoietic growth factors, including cytokines, are secreted by endothelial cells and fibroblasts. JAK2 phosphorylates STAT5 in normal hematopoietic stem cells following activation of cytokine receptors. However, BCR-ABL phosphorylates STAT5 at the same critical tyrosine residue close to the SH2 domain in CML cells, and activated STAT5 translocates to the nucleus [14,25].

Residual leukemia cells in bone marrow niches are exposed to many cytokines *in situ* [26]. Our results indicate that cytokine-enriched HS-5 conditioned medium protected CML cells from imatinib. Furthermore, we demonstrated that the imatinib inhibitory effect decreased when CML cells were co-cultured with HS-5 cells. This stromal
Figure 3 (See legend on next page.)
cell line secretes multiple cytokines that support hematopoietic progenitor proliferation. Treatment of K562 cells with imatinib in the presence of HS-5 conditioned medium resulted in only partial inhibition of cell growth, indicating that imatinib alone may not be sufficient to eradicate residual CML cells that reside within a cytokine-rich microenvironment. Thus, it is important to probe the cytokine-mediated leukemia stem cell signaling pathways as targets for combined treatments with TKIs to develop more efficient therapies for patients with CML.

In this study, we analyzed the ability of cytokine signaling to protect CML cells. A previous study revealed GM-CSF-mediated imatinib and nilotinib resistance through BCR-ABL independent activation of the JAK2/STAT5 pathway [27]. We demonstrated that inhibiting JAK2 by either JAK2 siRNA transfection or the JAK2 inhibitor TG101348 downregulated STAT5 activity. Moreover, STAT5 phosphorylation decreased considerably and PARP activity increased following co-treatment with imatinib and TG101348 in Ph+ leukemia cells including primary CD34-positive cells. Inhibiting STAT5 in leukemia was sufficient to prevent leukemia cell proliferation. JAK2 functions downstream of BCR-ABL. Although we did not attempt to combine the two drugs at their IC50s in this cell line, we showed that inhibiting JAK2 resulted in reduced STAT5 activity and enhanced imatinib efficacy even when leukemia cells were protected by hematopoietic stromal cells-mediating cytokine/chemokine production.

We also examined the effect of TG101348 on cytokine expression in HS-5 cells using a cytokine array containing 36 different cytokines. We observed that expression levels of several cytokines, such as GM-CSF, G-CSF, and IL-6, decreased considerably after treatment. Because GM-CSF and IL-6 are involved in maintenance of hematopoietic stem cells, these cytokines suppress apoptosis and regulate cell viability, growth, and differentiation [28]. Thus, activating cytokine-mediated JAK2/STAT5 signaling may circumvent the need for BCR-ABL signaling and cell survival [29]. Here, we demonstrated that blocking cytokine signaling using a JAK2 inhibitor in combination with imatinib might be an effective strategy to eradicate residual CML cells in vitro and in vivo. Cytokine-mediated signaling may not be critical for cell survival when BCR-ABL signaling is activated; however, it is possible that residual CML cells treated with imatinib can be rescued through a cytokine-triggered JAK2/STAT5 signaling pathway.

**Conclusions**

Our results indicate that co-treatment with imatinib and JAK2 inhibitors may have the potential for targeting residual CML cells by enhancing imatinib efficiency and reducing cytokine production by stromal cells. Therefore, this approach may represent an important therapeutic strategy for patients with CML.

**Methods**

**Cell culture and reagents**

The BCR-ABL-positive leukemia cell line K562 and human bone marrow stromal cell line HS-5 were obtained from the American Type Culture Collection (Rockville, MD, USA). Cells were cultured in the Roswell Park Memorial Institute 1640 medium containing 10% fetal bovine serum and maintained at 37°C in a 5% CO2 humidified atmosphere. The JAK2 inhibitor TG101348 was purchased from Shanghai APIs Chemical (Shanghai, China) and the ABL kinase inhibitor imatinib was provided by Novartis Pharma AG (Basel, Switzerland). Stock solutions of TG101348 were prepared in dimethyl sulfoxide, while that of imatinib was prepared in distilled water. These stock solutions were further diluted in growth medium to achieve the desired concentrations. Antibodies (Abs) against phosphor-Ab1, phospho Crk-L, STAT5, MAPK, cleaved caspase-3, and PARP were purchased from Cell Signaling Technology (Danvers, MA, USA). Erk-1, Crk-L, and STAT5 Abs were purchased from BD Biosciences (San Jose, CA, USA). The anti-Ab1 Ab was purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Other reagents were obtained from Sigma-Aldrich (St. Louis, MO, USA).

**Primary BCR-ABL-positive and normal control cells**

This study protocol was approved by the Institutional Review Board of Tokyo Medical University, and written informed consent was provided by all patients in accordance with the Declaration of Helsinki. Primary samples were collected from untreated peripheral blood of patients with CML or from the bone marrow of normal
healthy donor after obtaining written informed consent. The peripheral blood was collected in heparinized tubes, and mononuclear cells were separated using LymphoSep (Immuno-Biological Laboratories, Minneapolis, MN, USA). These cells were either used immediately or cryopreserved in liquid nitrogen until use.

**Cell proliferation assay**

Cells were seeded in 24- or 96-well plates at a density of $8 \times 10^4$ or $8 \times 10^3$ cells/well. Next, cells were treated with the inhibitors at the indicated concentrations: imatinib, 100 nM to 2 μM; and TG101348, 100 nM to 1 μM. Vi-
able cells were either counted using trypan blue

---

**Figure 4** JAK2 siRNA transfected K562 cells had increased sensitivity to imatinib. (A) K562 cells were transfected with JAK2 siRNA or a control siRNA. Cell lysates were analyzed by immunoblotting 72 h after transfection using Jak2 and β-actin Abs. Blots were scanned and optical densities were determined using the ImageJ system. (B) K562 and siRNA-transfected K562 cells were cultured at a concentration of $8 \times 10^4$/mL in the presence or absence of feeder cells. The cells were treated with 1 μM imatinib for 72 h. Viable cell numbers were calculated. Results are representative of three separate experiments. (C) K562 and siRNA-transfected K562 cells were treated with imatinib for 24 h, and total extracts were examined by immunoblotting using anti-phospho ABL, ABL, phospho-Crk-L, Crk-L, phospho-MAPK, Erk-1 and β-actin Abs. Blots were scanned and optical densities were determined using ImageJ software.
exclusion or were stained with a cell counting kit solution (Dojin, Kumamoto, Japan) and measured spectrophoto- metrically (A450) to determine cell viability. In some experiments, cells were co-cultured with human stromal cells. After cultivating the HS-5 cells at a density of 1 × 10⁵ cells/well in 24-well plates overnight, the K562 cells were plated onto the HS-5 cells, cultured for 3 days, and analyzed for cell proliferation. To analyze the activity of the soluble factors produced by HS-5 cells, K562 cells were cultured for 72 h in the presence of HS-5 conditioned medium from cultures that were either not treated with imatinib or treated with the drug at the indicated concentrations. Cell proliferation was then analyzed.

**siRNA transfection**
siRNAs targeting the JAK family members were purchased from Santa Cruz Biotechnology (sc-39099). K562 cells were transfected with a siRNA targeting JAK2 by electroporation, as described previously [30].

**Immunoblotting**
Immunoblotting was performed as described previously [31]. After different treatments were performed as indicated above, cells were collected by centrifugation and lysed by sonication using the radioimmunoprecipitation assay lysis buffer. Protein content in the lysates was determined using a protein assay kit (Bio-Rad Laboratories,
Cytokine array
After culturing HS-5 cells in the presence or absence of TG101348, the culture medium was collected. Cytokine levels in the medium were measured using the human cytokine panel A (Proteome Profiler™) (R&D Systems, Minneapolis, MN, USA). Horseradish peroxidase substrate was used to detect protein expression, and data were visualized using Kodak Biomax Light film. Arrays were scanned and optical densities were determined using Image J software.

In vivo studies
Six-week-old female BALB/c nude mice were purchased from CLEA Japan Inc. (Tokyo, Japan). Mice were injected subcutaneously with $1 \times 10^7$ Ba/F3 wild-type BCR-ABL cells. Mice were treated after 5 days with 40 mg/kg imatinib intraperitoneally or 30 mg/kg TG101348 orally or a combination of the two agents for 5 days per week. Control mice were treated with phosphate-buffered saline. Tumor sizes were analyzed every day. The average tumor weight per mouse (n = 6) was calculated.

Statistical analysis
We used Student’s t-test to determine differences in response to the various treatments. p < 0.05 was considered statistically significant.

Abbreviations
Ph: Philadelphia chromosome; Tki: Tyrosine kinase inhibitor; CML: Chronic myeloid leukemia; JAK: Janus kinase; GM-CSF: Granulocyte macrophage colony-stimulating factor; STAT: Signal transducer and activator of transcription; IL: Interleukin.

Competing interests
The authors declare no competing interests.

Authors’ contributions
SO, TT, SK, YT, and KO conceived and designed the experiments; SO performed the experiments; and SO, TT, SK, YT, and KO contributed reagents and wrote the manuscript. All authors read and approved the final manuscript.

Acknowledgments
This study was supported by a “High-Tech Research Center” Project for private universities, a matching fund subsidy from the Ministry of Education, Culture, Sports, Science and Technology (MEXT); and by the “University-Industry Joint Research Project” for private universities, a matching fund subsidy from MEXT. This study was also supported by Grants-in-Aid for Scientific Research from MEXT.

References
1. Sattler M, Griffin JD: Molecular mechanisms of transformation by the BCR-ABL oncogene. Semin Hematol 2003, 40(suppl 1):4–10.
2. Kantarjian HM, Talpaz M, Giles F, O’Brien S, Cortes J: New insights into the pathophysiology of chronic myeloid leukemia and imatinib resistance. Ann Intern Med 2006, 145:913–923.
3. Helgason OV, Kavella M, Holyoake TL: Kill one bird with two stones: potential efficacy of BCR-ABL and autophagy inhibition in CML. Blood 2011, 118:2035–2043.
4. Savelyev CL, McLaughlin J, Witte ON: Genetic requirement for Ras in the transformation of fibroblasts and hematopoietic cells by the Bcr-Abl oncogene. J Exp Med 1995, 181:307–313.
5. Skorski T, Bellacosa A, Niebr Biovaska-Skorika M, Majewski M, Martinez R, Choi JK, Trotta R, Wilkowski P, Perrotti D, Chan TO, Wark MA, Tschis PN, Calabretta B: Transformation of hematopoietic cells by BCR/ABL requires activation of a PI3k/Akt-dependent pathway. EMBO J 1997, 16:6151–6161.
6. Chai SK, Nichols GL, Rothman P: Constitutive activation of JAKs and STATs in BCR-ABL-expressing cell lines and peripheral blood cells derived from leukemic patients. J Immunol 1997, 159:4720–4728.
7. Roskoski Jr TJ: STI-571: an anticancer protein-tyrosine kinase inhibitor. Biochem Biophys Res Commun 2003, 309:709–717.
8. Druker BJ, Guilhot F, O’Brien SG, Gathmann I, Kantarjian H, Gattermann N, Deininger MW, Silver RT, Goldman JM, Stone RM, Cervantes F, Hochhaus A, Powell BL, Gabrilove JL, Rousset P, Reiffers J, Cornelissen JJ, Hughes T, Agis H, Fischer T, Verhoef G, Shepherd J, Saglio G, Grwothaw A, Nielsen JL, Radich JP, Simonsson B, Taylor K, Baccarani M, So C, et al: Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 2006, 355:2408–2417.
9. Mahon FX, Réa D, Guilhot J, Guilhot F, Huguet F, Nicoletti F, Legros L, Charbonnier A, Guerci A, Varet B, Etienne G, Reiffers J, Rousset P: Intergruppe Français des Leucémies Myéloïdes Chroniques: Discontinuation of imatinib in patients with chronic myeloid leukemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial. Lancet Oncol 2010, 11:1029–1035.
10. Murray PJ: The JAK-STAT signaling pathway: input and output integration. J Immunol 2007, 178:2623–2629.
11. Wiedon H, Roberts PJ, Watts MJ, Linch DC: Changes in signal transduction downstream from the granulocyte-macrophage colony-stimulating factor receptor during differentiation of primary hemopoietic cells. Exp Hematol 1999, 27:1077–1086.
12. Nagata Y, Todokoro K: Interleukin 3 activates not only JAK2 and STAT5, but also Tyk2, STAT1, and STAT3. Biochem Biophys Res Commun 1996, 221:785–789.
13. Sloma I, Jiang X, Eaves AC, Eaves CJ: Insights into the stem cells of chronic myeloid leukemia. Leukemia 2010, 24:1823–1833.
14. Pardanani A, Gottlieb JR, Jamieson C, Cortes JE, Talpaz M, Stone RM, Silverman MH, Gilliland DG, Shorr J, Telfer A: Safety and efficacy of TG101348, a selective JAK2 inhibitor, in myelofibrosis. J Clin Oncol 2011, 29:789–796.
15. Vainchenker W, Constantinescu SN: JAK/STAT signaling in hematological malignancies. Oncogene 2013, 32:2601–2613.
16. Xu W, Chen B, Tong Y: Chronic myeloid leukemia patient with co-occurrence of BCR-ABL junction and JAK2 V617F mutation. Int J Hematol 2014, 99:87–90.
17. Lee YJ, Moon JH, Shin HC, Seo JW, Han SA, Seo SK, Sohn SK: Two CML patients who subsequently developed features of essential thrombocythemia with JAK2-V617F mutation while in complete cytogenetic remission after treatment with imatinib mesylate. Int J Hematol 2013, 87:804–807.
leukemia phenotype acquisition during hydroxyurea treatment. 

21. Samanta AK, Chakraborty SN, Wang Y, Schlette E, Reddy EP, Arlinghaus RB: Destabilization of Bcr-Abl/Jak2 network by a Jak2/Abl kinase inhibitor ON044580 overcomes drug resistance in blast crisis chronic myelogenous leukemia (CML). Genes Cancer 2010, 1:346–359.

22. Cogle CR: Overcoming chronic myeloid leukemia stem cell resistance to imatinib by also targeting JAK2. J Natl Cancer Inst 2013, 105:378–379.

23. Nakao T, Kim S, Ohta K, Kawano H, Hino M, Miura K, Tatsurni N, Iwao H: Role of mitogen-activated protein kinase family in serum-induced leukemia inhibitory factor and interleukin-6 secretion by bone marrow stromal cells. Br J Pharmacol 2002, 136:975–984.

24. Ernst T, Hochhaus A: Chronic myeloid leukemia: clinical impact of BCR-ABL1 mutations and other lesions associated with disease progression. Semin Oncol 2012, 39:58–66.

25. Warsch W, Kollmann K, Eckelhart F, Fajmann S, Cerny-Reiterer S, Hölzl A, Gleiñner KV, Dworzak M, Mayerhofer M, Hoernemann G, Herrmann H, Sillaber C, Egger G, Vollet P, Montigl R, Seul V: High STATS levels mediate imatinib resistance and indicate disease progression in chronic myeloid leukemia. Blood 2011, 117:3409–3420.

26. Corbin AS, Agarwal A, Loriaux M, Cortes J, Deininger MW, Druker BJ: Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity. J Clin Invest 2011, 121:396–409.

27. Wang Y, Cai D, Bredel C, Baret C, Erpen P, Manley PW, Hochhaus A, Neubauer A, Burchet A: Adaptive secretion of granulocyte-macrophage colony-stimulating factor (GM-CSF) mediates imatinib and nilotinib resistance in BCR/ABL + progenitors via JAK-2/STAT-5 pathway activation. Blood 2007, 109:2147–2155.

28. Mohamed AA, Ibrahim AM, El-Masty MW, Mansour IM, Khroshied MA, Gouda HM, Rad RM: Ex vivo expansion of stem cells: defining optimum conditions using various cytokines. Lab Hematol 2006, 12:86–93.

29. McCubrey JA, Steelman LS, Abrams SL, Bertrand FE, Ludwig DE, Bâsceke J, Libra M, Stivala F, Milella M, Tafuri A, Martelli AM: Targeting survival cascades induced by activation of Ras/Raf/MEK/ERK, PI3K/PTEN/Akt/mTOR and Jak/STAT pathways for effective leukemia therapy. Leukemia 2008, 22:708–722.

30. Okabe S, Tauchi T, Tanaka Y, Katagiri S, Ohyashiki K: Effects of the hedgehog inhibitor GDC-0449, alone or in combination with dasatinib, on BCR-ABL-positive leukemia cells. Stem Cells Dev 2012, 21:2939–2948.

31. Okabe S, Tauchi T, Tanaka Y, Ohyashiki K: Efficacy of ponatinib against ABL tyrosine kinase inhibitor-resistant leukemia cells. Biochem Biophys Res Commun 2013, 435:506–511.